SMC combination therapy for the treatment of cancer
US10441654B2 · kind B2 · utility
2Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 26, 2015 |
| Grant date | Oct 15, 2019 |
| Priority date | — |
| Expiry date | Jan 26, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/20134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.